Threshold Pharmaceuticals (THLD) receives funding to begin phase 1 trials for its hypoxia...

|About: Threshold Pharmaceuticals, ... (THLD)|By:, SA News Editor

Threshold Pharmaceuticals (THLD) receives funding to begin phase 1 trials for its hypoxia activated prodrug TH-302. The study will determine the safety and effectiveness of using TH-302 in combination with Glaxo's (GSK) Votrient in advanced solid tumors. THLD shares +2.4% premarket.